OVERVIEW OF PRIMARY ENDPOINTS, PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) FOR NON-SMALL CELL LUNG CANCER (NSCLC): THEIR VALUE IN TREATMENT DECISIONS AND PATIENT CARE

被引：0
|
作者：
Heron, Louise [1 ]
Chouaid, Christos [2 ]
Vergnenegre, Alain
Bischoff, Helge [3 ]
Walzer, Stefan [4 ]
机构：
[1] Mapi Values, Value Sight & Commun, Boston, MA USA
[2] Hop St Antoine, Lille, France
[3] Univ Heidelberg, Thoraxklin, D-6900 Heidelberg, Germany
[4] F Hoffmann La Roche Pharmaceut AG, Basel, Switzerland
来源：
JOURNAL OF THORACIC ONCOLOGY | 2011年 / 6卷 / 06期
关键词：
Progression; survival; endpoints;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S1447 / S1448
页数：2
相关论文
共 50 条
  • [31] Association of progression-free survival (PFS) with overall survival (OS) in advanced biliary tract cancer (BTC): A trialand patient-level analysis
    Castet, F.
    Fabregat-Franco, C.
    Kim, J. W.
    Rimini, M.
    Lacasta, A.
    Kang, M.
    Salani, F.
    Castillo Trujillo, A. O.
    Lopez Valbuena, D. E.
    Basagana-Farres, M.
    Adeva, J. A.
    Munoz Martin, A. J.
    Hyung, J.
    Rimassa, L.
    Casadei Gardini, A.
    Yoo, C.
    Macarulla Mercade, T.
    ANNALS OF ONCOLOGY, 2024, 35 : S121 - S121
  • [32] Use of progression-free survival (PES) as an endpoint in advanced non-small cell lung cancer (NSCLC) trials: FDA perspective
    Malik, S. M.
    Ibrahim, A.
    Sridhara, R.
    Justice, R. L.
    Pazdur, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [33] MATCHING-ADJUSTED INDIRECT TREATMENT COMPARISONS (MAIC) OF THE EFFECT OF LORLATINIB VERSUS CHEMOTHERAPY ON OVERALL SURVIVAL (OS) AND PROGRESSION-FREE SURVIVAL (PFS) FOR PATIENTS WITH SECOND-LINE OR LATER ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
    Smith, S.
    Albuquerque de Almeida, F.
    Ines, M.
    Iadeluca, L.
    Cooper, M.
    VALUE IN HEALTH, 2020, 23 : S421 - S422
  • [34] The impact of insurance status on progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
    Castro, Daniela
    Tripathi, Nishita
    Sayegh, Nicolas
    Gebrael, Georges
    Li, Xiaochen
    Meza, Luis
    Zengin, Zeynep
    Chehrazi-Raffle, Alex
    Govindarajan, Ameish
    Dizman, Nazli
    Ebrahimi, Hedyeh
    Chawla, Neal
    Mercier, Benjamin
    Hsu, Joann
    Shi, Jessica
    Philip, Errol
    Bergerot, Cristiane
    Barragan-Carrillo, Regina
    Pal, Sumanta
    ONCOLOGIST, 2023, 28 : S5 - +
  • [35] Influence of clinical trial participation with regard to overall survival (OS) and progression-free survival (PFS) for patients with advanced breast cancer
    Kiechle, M.
    Simstich, N. S.
    Schwarz-Boeger, U. R.
    Paepke, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [36] Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non-Small Cell Lung Cancer Trials Using Real-World Data
    Ton, Thanh G. N.
    Pal, Navdeep
    Trinh, Huong
    Mahrus, Sami
    Bretscher, Michael T.
    Machado, Robson J. M.
    Sadetsky, Natalia
    Chaudhary, Nayan
    Lu, Michael W.
    Riely, Gregory J.
    CLINICAL CANCER RESEARCH, 2022, 28 (13) : 2844 - 2853
  • [37] Correlation between progression-free and overall survival in a meta-analysis of aggregated survival data from patients with non-small cell lung cancer
    Aksenov, Sergey
    Lee, Daniel
    Edlund, Helena
    Minchella, Kaitlyn
    Xu, Hongmei
    Dunyak, James
    Al-Huniti, Nidal
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2017, 44 : S63 - S64
  • [38] Real world experience of hypofractionated radical radiotherapy for non-small cell lung cancer (NSCLC) during the COVID-19 pandemic: a well-tolerated radiotherapy schedule with acceptable progression-free (PFS) and overall survival (OS)
    Jeyin, Nidhish
    Kidane, Ghirmay
    Withers, Dominic
    Ball, Simon
    Tarver, Kathryn
    LUNG CANCER, 2023, 178 : S63 - S63
  • [39] Meta-analysis of progression-free survival as a predictor of overall survival in locally advanced or metastatic non-small cell lung cancer trials.
    Turner, Evadne Jane
    McCloud, Philip
    Germanos, Peter
    Dehle, Francis
    Norris, Sarah
    Tan, Jonathan
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [40] Statistical considerations and endpoints for clinical lung cancer studies: can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced no(n)small-cell lung cancer?
    Pilz, Lothar R.
    Manegold, Christian
    Schmid-Bindert, Gerald
    TRANSLATIONAL LUNG CANCER RESEARCH, 2012, 1 (01) : 26 - 35
12345